Cost‐effectiveness analysis of new drugs for chronic hepatitis C: The importance of updating utility values

Cortesi, P.A.; Scalone, L; Mantovani, LG

doi:10.1002/hep.27316

Cited by 2 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another instance, not all relevant treatment options for a given population were considered . In another case, the utility indexes used to calculate QALYs were not up to date or not correct . Also, only the two individual‐based models accounted for a higher risk of non‐liver‐related death based on the results of the Third National Health and Nutrition Examination Survey .…”

Section: Health Economics Models In Liver Diseases: the Case Of Hcvmentioning

confidence: 99%

Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases

2016

View full text Add to dashboard Cite

show abstract

Section: Health Economics Models In Liver Diseases: the Case Of Hcvmentioning

confidence: 99%

Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases

2016

View full text Add to dashboard Cite

show abstract

Evaluation of health status in patients with hepatitis c treated with and without interferon

Ragusa¹,

Bertino²,

Bruno

et al. 2018

Health Qual Life Outcomes

View full text Add to dashboard Cite

BackgroundThe evolution of technology in healthcare has increased the health care’s costs and, the universal healthcare systems, in developed countries, need to ensure proper allocation of resources. Thus, the major issue is assessing the effectiveness of new medical technologies. The evaluation of quality of life in response to new treatments has become a key indicator in chronic conditions for which medical interventions are evaluated not only in terms of increasing the number of expected life years but also in terms of increasing quality of life. The aim of this observational study was to verify whether a simple instrument (EQ-5D-5 L) can capture variations in health-related quality of life (HRQoL) and allow us to evaluate the impact of different drug treatment protocols in patients with hepatitis C virus (HCV) on daily activities.MethodsSixty six patients with HCV were consecutively enrolled in the Hepatology Unit at the University Hospital of Catania “G. Rodolico”. Sixteen patients received new direct-acting-antiviral agents (DAAs) plus pegylated alpha interferon (Peg-α-IFN) protocol (Group A) and 50 DAAs IFN free protocol (Group B).The EQ-5D-5 L® questionnaire and visual analog scale (VAS) were given to both groups to calculate coefficient’s utility. We used the EQ-5D-5 L Crosswalk Index Value Calculator to obtain the utility EQIndex and both parametric and non parametric tests for the statistical analysis.ResultsThe biopsy taken at the beginning of treatment showed comparable cell damage in both groups. The difference in the VAS results was negative for patients who received protocols containing IFN (indicating decreased quality of life),whereas it was positive in patients treated with IFN-free protocols. The baseline EQIndex did not reveal any differences between the two treatment groups. The post-treatment EQIndex was statistically better in the groups that received IFN-free therapy.ConclusionsWhen innovative treatments are introduced into clinical practice, assessing quality of life is mandatory to determine their benefits. The instruments used in the present study are effective in detecting the areas in which improvement has occurred. These instruments can be easily managed by general practitioners for follow up of progression of the disease and referred to the specialist.

show abstract

Cost‐effectiveness analysis of new drugs for chronic hepatitis C: The importance of updating utility values

Cited by 2 publications

References 6 publications

Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases

Effective but costly: How to tackle difficult trade‐offs in evaluating health improving technologies in liver diseases

Evaluation of health status in patients with hepatitis c treated with and without interferon

Contact Info

Product

Resources

About